TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12086380
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (40 mg/daily)
Study: 9695894
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy (theophylline, inhaled bronchodilators, steroids, antianxiolytics, antidepressants)
Study: 9695894
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle therapy (inspiratory muscle training, inspiratory muscle rest)
Study: 7888387
Drug: Craniospinal irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Craniospinal irradiation and chemotherapy
Study: 2171446
Drug: Aluminum plus
Normalized name: aluminum hydroxide / magnesium hydroxide / simethicone Chewable Tablet [Mintox Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum plus citrate (as Shohl's solution)
Study: 21278617
Drug: ACWY‐TT (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACWY‐TT (tetravalent meningococcal conjugate vaccine)
Study: 21278617
Drug: Men‐PS (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men‐PS (licensed tetravalent meningococcal polysaccharide vaccine)
Study: 19032560
Drug: Lidocaine 10
Normalized name: lidocaine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10 mg/ml
Study: 17156291
Drug: Placebo (rabies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (rabies vaccine)
Study: 17156291
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine (administered to placebo patients at trial closeout)
Study: 15494897
Drug: Valacyclovir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir at 1000 mg twice daily for 5 days
Study: 18008230
Drug: Valacyclovir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir at 500 mg twice daily
Study: 11226098
Drug: FBM: fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBM: fentanyl (25 microg) and bupivacaine (2.5 mg) plus morphine (150 microg)
Study: 11226098
Drug: FB: fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB: fentanyl (25 microg) and bupivacaine (2.5 mg)
Study: 11154952
Drug: CHO solution
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO solution containing 1.7 g CHO/kg(body weight)
Study: 11154952
Drug: Isocaloric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric solution containing 1.2 g CHO/kg(body weight) plus 0.5 g protein/kg(body weight) (including 5 g arginine)
Study: 8989740
Drug: Usual-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-protein diet (1.3 g/kg per day)
Study: 31685813
Drug: Topiramate (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (50-200 mg/day)
Study: 20456211
Drug: Glipizide 5
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5 mg/day (up-titrated to 20 mg/day)
Study: 17429836
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with imatinib (Ind(IM))
Study: 17429836
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with multiagent, age-adapted chemotherapy (Ind(chemo))
Study: 17429836
Drug: Combined imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined imatinib and chemotherapy consolidation
Study: 16338283
Drug: Sitagliptin (1.5-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (1.5-600 mg)
Study: 27811278
Drug: Testosterone/Oestradiol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone/Oestradiol combination
Study: 25361769
Drug: γ-Tocopherol (γ-T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-Tocopherol (γ-T) rich mixture of tocopherols (γ-TmT), 500 mg
Study: 25361769
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) with γ-TmT
Study: 25361769
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) alone (placebo)
Study: 16413892
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg, remifentanil: propofol (1:500) at 40 microg/kg/min
Study: 16413892
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg, fentanyl 1 microg/kg, propofol at 140 microg/kg/min
Study: 12380231
Drug: Fermi-type rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermi-type rabies vaccine (0.25 ml) administered to groups 2-5 of mice for 14 consecutive days.
Study: 12380231
Drug: Fermi-type rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermi-type rabies vaccine for human PEP (prescribed dosage).
Study: 12380231
Drug: Phenolized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenolized saline (0.25 ml) administered to group 1 of mice for 14 consecutive days.
Study: 9251974
Drug: 0.25% quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% quinine hydrochloride solution
Study: 8119426
Drug: Topical amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amethocaine
Study: 3670697
Drug: Motor Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor Activation Therapy (MAT)
Study: 3670697
Drug: Buflomedil +
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil + Motor Activation Therapy (MAT)
Study: 29338476
Drug: Carboxytherapy (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxytherapy (subcutaneous infusion)
Study: 28449368
Drug: omarigliptin 25
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: omarigliptin 25 mg once weekly
Study: 28449368
Drug: sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 50 mg once daily
Study: 26612980
Drug: SHRED (multi-ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHRED (multi-ingredient supplement)
Study: 23612106
Drug: 27.6 mg
Normalized name: alanine 27.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27.6 mg of iron (ferrous fumarate enriched with 13% haem iron) daily for 12 weeks
Study: 23612106
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ferrosulphate daily for 12 weeks
Study: 21225090
Drug: NOMAC/E2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMAC/E2 (2.5 mg/1.5 mg)
Study: 21225090
Drug: LNG/EE (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE (100 μg/20 μg)
Study: 18394916
Drug: Postoperative concomitant
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative concomitant chemo-radiation consisting of 60Gy external-beam radiotherapy and temozolomide (TMZ) administered concomitantly (75mg/m² daily) and after radiotherapy (150-200mg/m², for 5 days every 4 weeks)
Study: 18394916
Drug: Nitrosourea-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrosourea-based chemotherapy or temozolomide re-challenge at time of recurrence/progression
Study: 16460667
Drug: Treatment expectancy
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment expectancy
Study: 8844442
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 15 days (morning administration)
Study: 8844442
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 15 days (evening administration)
Study: 6588486
Drug: Metronidazole (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1500 mg infused during 50 minutes)
Study: 6588486
Drug: Tinidazole (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (1500 mg infused during 50 minutes)
Study: 29533000
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg until disease progression or unacceptable toxicity)
Study: 24423369
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow cell (BMC) therapy in non-smokers
Study: 24423369
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow cell (BMC) therapy in smokers
Study: 16796710
Drug: Nadroparin 2850
Normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 2850 IU (0.3 mL)
Study: 16796710
Drug: Enoxaparin 4000
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 4000 IU (40 mg)
Study: 12752349
Drug: PCM (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCM (pantoprazole 40 mg, clarithromycin 500 mg, metronidazole 500 mg)
Study: 14632678
Drug: PCA (pantoprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (pantoprazole, clarithromycin, amoxicillin 1000 mg)
Study: 3815457
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide (15 mg)
Study: 21414133
Drug: Flapless implants
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flapless implants
Study: 21414133
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants (flap-group)
Study: 17697901
Drug: Ebastine fast-dissolving
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ebastine fast-dissolving tablet 20 mg
Study: 17697901
Drug: Desloratadine capsule
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine capsule 5 mg
Study: 3578948
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 482.5 +/- 186.6 ml X min‐1 (Group A)
Study: 3578948
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 2000 ml X min‐1 (Group B)
Study: 3578948
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow adjusted to 7145 +/- 986 ml X min‐1 (Group C)
Study: 26824527
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin alone
Study: 26824527
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin with 0.5 mg dutasteride daily for 12 months
Study: 23275019
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered golimumab
Study: 21641522
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy at 10,000 lux
Study: 21641522
Drug: Usual standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual standard of care and light therapy at 50 lux
Study: 18047629
Drug: 2.5% CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% CP 1.0 mL (Group A)
Study: 18047629
Drug: 2.5% CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% CP 1.2 mL (Group B)
Study: 18047629
Drug: 2.5% CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% CP 1.4 mL (Group C)
Study: 18047629
Drug: 2.5% CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% CP 1.6 mL (Group D)
Study: 17195601
Drug: Neuroscience strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroscience strategies applied in psychological treatment research
Study: 11938860
Drug: Yinchen Dandao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinchen Dandao decoction (YCDDD) administered orally for 1 week starting 3 days after operation
Study: 9080642
Drug: Deslorelin (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deslorelin (2.2 mg, subcutaneously as a short-term implant)
Study: 8401637
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy following radical cystectomy
Study: 8401637
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy following cystectomy or aggressive TUR
Study: 25346595
Drug: Color-coded BP
Normalized name: SALON CODE Glam Hair Color Glam Brown KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color-coded BP booklet for daily home BP measurement
Study: 23744819
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg kg(‐1) i.v.
Study: 20593151
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU daily vitamin D
Study: 20593151
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU daily vitamin D
Study: 11964551
Drug: Indinavir (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (1200 mg orally)
Study: 9485556
Drug: Phenytoin (third
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (third dose)
Study: 7803948
Drug: Vinorelbine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine as second-line chemotherapy
Study: 7803948
Drug: Vinorelbine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (oral dosage form)
Study: 31990424
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg once daily (V20)
Study: 31990424
Drug: Rabeprazole 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 40 mg twice daily (R40)
Study: 20401354
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) alone or in conjunction with conservative treatment
Study: 20401354
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) prior to conservative treatment
Study: 20401354
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with biofeedback, conservative treatment, and/or self-care
Study: 16293806
Drug: Volumen (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumen (0.1% barium suspension), 1200 mL over 30 minutes
Study: 16293806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (water and methylcellulose solution), 1200 mL over 30 minutes
Study: 1676779
Drug: TPGS (d‐alpha‐tocopheryl‐polyethylene‐glycol‐1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPGS (d‐alpha‐tocopheryl‐polyethylene‐glycol‐1000 succinate) 25 mg/kg daily
Study: 29320594
Drug: Oxymetazoline hydrochloride
Normalized name: Oxymetazoline Hydrochloride
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline hydrochloride cream 1.0% applied once daily for 29 days
Study: 29320594
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied once daily for 29 days
Study: 29320594
Drug: Oxymetazoline hydrochloride
Normalized name: Oxymetazoline Hydrochloride
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline hydrochloride cream 1.0%
Study: 22034656
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 μg p.o.)
Study: 18221408
Drug: G12 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: G12 (12 weeks therapy)
Study: 18221408
Drug: G24 (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: G24 (24 weeks therapy)
Study: 18221408
Drug: G36 (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: G36 (36 weeks therapy)
Study: 18221408
Drug: G48 (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: G48 (48 weeks therapy)
Study: 15739210
Drug: CHO (carbohydrate-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (carbohydrate-rich drink) 50 kcal/100 ml, 290 mOsm/kg; 800 ml evening before surgery and 400 ml 2 hours before anaesthesia
Study: 15739210
Drug: Placebo; 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; 800 ml evening before surgery and 400 ml 2 hours before anaesthesia
Study: 15087294
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg/day for 7 days)
Study: 9309457
Drug: NSAID (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (600 mg of Sulindac for one day)
Study: 9309457
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (transdermal system 50 micrograms/d, twice a week, Systen) for 3 months
Study: 2943820
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg i.v. pretreatment
Study: 24573971
Drug: Cisatracurium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.03 mg/kg)
Study: 22945403
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (280 mg docosahexaenoic acid and 110 mg eicosapentaenoic acid)
Study: 18682511
Drug: Teriparatide after
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide after prior treatment with risedronate
Study: 18682511
Drug: Teriparatide after
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide after prior treatment with alendronate
Study: 15885613
Drug: Identification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identification of specific impairing drugs
Study: 12817157
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose 2 mg, range 0.5-4 mg) added to mood stabilizers
Study: 10440305
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated human rotavirus vaccine 89-12 (1x10^5 plaque-forming units)
Study: 12404166
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated human rotavirus vaccine 89-12
Study: 7825537
Drug: Soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy formula with added selenate (SF+Se, 0.17 mumol Se/L)
Study: 7825537
Drug: Soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy formula (SF, 0.028 mumol Se/L)
Study: 2141057
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen and fenoterol (IBF)
Study: 638411
Drug: Dietary restriction
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary restriction and laxatives
Study: 7575762
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (0.8 g single daily dose)
Study: 7575762
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (0.4 g two daily doses)
Study: 2256719
Drug: Chemoresistance testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoresistance testing at initiation of therapy
Study: 6989684
Drug: tolciclate 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolciclate 1% cream
Study: 6989684
Drug: miconazole 2%
Normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: miconazole 2% cream
Study: 26536843
Drug: Treatment-as-usual (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control group) for high-risk patients
Study: 18271282
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day vitamin E (E400)
Study: 18271282
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day vitamin E (E200)
Study: 18271282
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day vitamin C (C250)
Study: 15673408
Drug: Pexelizumab bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab bolus (2.0 mg/kg) + placebo infusion
Study: 15673408
Drug: Pexelizumab bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab bolus (2.0 mg/kg) + pexelizumab infusion (0.05 mg/kg/hour for 24 hours)
Study: 15673408
Drug: Placebo bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus + placebo infusion
Study: 12151925
Drug: P6 acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: P6 acupoint injections
Study: 2240495
Drug: Triclofos 70
Normalized name: Triclofos
DrugBank: Triclofos (DB06753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclofos 70 mg/kg orally 90 minutes before operation
Study: 206923
Drug: TZM 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZM 0.25 mg
Study: 206923
Drug: FZP 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: FZP 15 mg
Study: 27329506
Drug: Daily intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intermittent hypoxia (IH) combined with body weight-supported treadmill training (BWSTT)
Study: 26073353
Drug: Amfepramone 75
Normalized name: Amfépramone
DrugBank: Diethylpropion (DB00937)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amfepramone 75 mg daily for 6 months
Study: 19251010
Drug: Fentanyl with
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl with midazolam (lower doses 2-3.5 mg)
Study: 19251010
Drug: Meperidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine with midazolam (lower doses 2-3.5 mg)
Study: 19251010
Drug: Fentanyl with
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl with midazolam (higher doses >= 4 mg)
Study: 19251010
Drug: Meperidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine with midazolam (higher doses >= 4 mg)